Corticosteroid treatment in sarcoidosis

Area of Science:

• Pulmonary Medicine
• Immunology
• Rheumatology

Background:

• Sarcoidosis currently lacks a definitive cure.
• Immunosuppressive and immunomodulatory drugs manage disease activity.
• Corticosteroids are the primary treatment, targeting pro-inflammatory cytokines and chemokines involved in granuloma formation.

Purpose of the Study:

• To evaluate the current role and limitations of corticosteroid therapy in managing sarcoidosis.
• To highlight the need for evidence-based guidelines regarding treatment decisions and long-term efficacy.
• To emphasize the necessity of well-designed clinical trials for future therapeutic advancements.

Main Methods:

• Review of existing literature on corticosteroid and immunosuppressive therapy for sarcoidosis.
• Analysis of criteria for initiating systemic treatment, focusing on disease severity and organ function.
• Discussion of the evidence gap concerning long-term benefits and optimal dosing strategies.

Main Results:

• Corticosteroids can improve symptoms and lung function in parenchymal sarcoidosis over 6-24 months.
• Systemic treatment is empirically indicated for neurological, cardiac, ocular, and hypercalcemic manifestations.
• No definitive proof of long-term survival benefit from corticosteroids exists despite over 50 years of use.

Conclusions:

• Treatment decisions for sarcoidosis should prioritize threatened organ functions over disease activity.
• Optimal corticosteroid or immunosuppressive therapy dosage and duration remain undetermined.
• Multicenter randomized controlled trials with long-term follow-up are crucial to assess the efficacy of current and novel agents in preventing fibrotic sequelae.